Application Detail

Description of Medical Service

Dinutuximab beta (monoclonal antibody therapy) used in conjunction with combination chemotherapy in patients who have experienced a primary relapse or are refractory to treatment. This treatment is currently funded for patients who achieve at least a partial response to induction chemotherapy and this application is seeking an extension of funding to include the primary relapse or refractory population.

Description of Medical Condition

Neuroblastoma is the most frequent cancer in children less than one year old. About half of patients with neuroblastoma are classified as having high-risk disease. The treatment is intended for patients with high-risk neuroblastoma who experience primary (first) relapse or are refractory (do not respond) to treatment.

Reason for Application

Change to existing listing - Highly specialised therapies - National Health Reform Agreement Addendum

Medical Service Type

Therapeutic technology

Previous Application Number/s

1625

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 136 KB)
Application Summary (Word 27 KB)

PICO Set (PDF 1511 KB)
PICO Set (Word 557 KB)

Consultation Survey

Consultation Survey

PASC Consultation
Bypassing PASC

MSAC Consultation
MSAC consultation closes Friday 14 February 2025

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Bypassing PASC

ESC

13-14 February 2025

MSAC

3-4 April 2025